

# Resource Summary Report

Generated by [ASWG](#) on Aug 4, 2026

## Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

RRID:SCR\_025370

Type: Tool

---

### Proper Citation

Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR\_025370)

---

### Resource Information

**URL:** <https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/resources/resources-countess-ii.html>

**Proper Citation:** Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR\_025370)

**Description:** Fully automated cell counter and assay platform that uses optics and image analysis algorithms to analyze trypan blue-stained cells in suspension. Benchtop device that measures cell concentration and viability.

**Synonyms:** Countess II Automated Cell Counter

**Resource Type:** instrument resource

**Keywords:** cell counter, automated cell counter, assay platform, nalyze trypan blue-stained cells in suspension,

**Availability:** Commercially available

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR\\_025370.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_025370.pdf)

**Resource Name:** Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

**Resource ID:** SCR\_025370

**Alternate IDs:** Model\_Number\_Countess\_II

**Alternate URLs:** [https://assets.thermofisher.com/TFS-Assets/BID/manuals/MAN0014293\\_Countess\\_II\\_Automated\\_Cell\\_Counter\\_UG.pdf](https://assets.thermofisher.com/TFS-Assets/BID/manuals/MAN0014293_Countess_II_Automated_Cell_Counter_UG.pdf)

**Record Creation Time:** 20240524T053223+0000

## Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

No alerts have been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 10 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#).

Renatino Canevarolo R, et al. (2025) Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Research square.

Piccoli M, et al. (2025) Direct Current Stimulation (DCS) Modulates Lipid Metabolism and Intercellular Vesicular Trafficking in SHSY-5Y Cell Line: Implications for Parkinson's Disease. Journal of neurochemistry, 169(2), e70014.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. Molecular cancer therapeutics, 24(9), 1415.

Nelson AJ, et al. (2025) Lung-resident memory B cells maintain allergic IgE responses in the respiratory tract. Immunity, 58(4), 875.

Mattavelli G, et al. (2025) A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. Immunity.

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer research, 85(22), 4359.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. Redox biology, 84, 103649.

Governa P, et al. (2018) Effects of *Boswellia Serrata* Roxb. and *Curcuma longa* L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. *Pharmaceuticals* (Basel, Switzerland), 11(4).